Nitrogen Containing Other Than Solely As A Nitrogen In An Inorganic Ion Of An Addition Salt, A Nitro Or A Nitroso Doai Patents (Class 514/579)
  • Patent number: 11135173
    Abstract: A prolonged release multiple unit dosage form, preferably pellets, of cysteamine, cystamine or a pharmaceutically acceptable salt thereof, preferably cysteamine bitartrate, with a non gastro-resistant coating is described. The dosage form is particularly indicated for the administration to patients once or twice a day and it can be used also for pediatric administration.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: October 5, 2021
    Assignee: RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
    Inventors: Andrea Gazzaniga, Matteo Cerea, Alessandra Maroni, Marco Barchielli
  • Patent number: 10456370
    Abstract: Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 29, 2019
    Assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 10016374
    Abstract: The present invention relates to pharmaceutical composition of Cinacalcet or a pharmaceutically acceptable salt thereof comprising diluents, binders and lubricants, wherein said composition is substantially free of disintegrant. It further relates to process for preparing such compositions.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: July 10, 2018
    Assignee: Jubilant Generics Limited
    Inventors: Goutam Muhuri, Ravikumar Nithiyanandam, Ganesh Vinayak Gat, Swati Mukherjee, Bharat Bhushan
  • Patent number: 9718770
    Abstract: The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: August 1, 2017
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Patent number: 9675565
    Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: June 13, 2017
    Assignees: Drexel University, Rutgers, The State University of New Jersey
    Inventors: Sandhya Kortagere, Eldo V. Kuzhikandahil
  • Patent number: 9555014
    Abstract: This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: January 31, 2017
    Assignee: Radius Health, Inc.
    Inventors: Louis O'Dea, C. Richard Lyttle, Jonathan Guerriero
  • Patent number: 9498450
    Abstract: The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: November 22, 2016
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Barbara Ellers-Lenz, Tanja Rosenberg, Hagen Kruger, Michael Althaus
  • Patent number: 9066856
    Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 30, 2015
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Hui-rong Shen, Clark E. Tedford
  • Patent number: 9012440
    Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: April 21, 2015
    Assignee: Laboratorios del Dr. Esteve, S.A.
    Inventors: Carlos Ramon Plata Salaman, Nicolas Tesson
  • Patent number: 8980951
    Abstract: Bicyclic sesquiterpene compounds exhibiting antifungal characteristics are formulated into antifungal compositions for use in the treatment of fungal infections in humans, animals, and plants. Particularly, sesquiterpene alcohols derived from drimane have been discovered to possess broad-spectrum antifungal characteristics. Exemplary antifungal sesquiterpene compounds include albicanol and drimenol, which have been shown effective against a number of pathogenic fungi.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: March 17, 2015
    Assignee: Kansas State University Research Foundation
    Inventors: Govindsamy Vediyappan, Duy H. Hua
  • Patent number: 8980318
    Abstract: Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit has a diameter of from 0.1 to less than 6 mm.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: March 17, 2015
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Bernhard Hauptmeier, Brigitte Purmann
  • Patent number: 8952057
    Abstract: Compositions containing polymetal complexes are useful in treating anorectal disorders.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: February 10, 2015
    Assignee: JR Chem, LLC
    Inventor: José E. Ramirez
  • Publication number: 20150018425
    Abstract: The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 15, 2015
    Inventors: Barbara ELLERS-LENZ, Tanja ROSENBERG, Erhard SEILLER, Hagen KRÜGER, Michael ALTHAUS
  • Patent number: 8932626
    Abstract: An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: January 13, 2015
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventors: Akiko Katayama, Katsuyuki Inoo
  • Patent number: 8933130
    Abstract: The present invention is directed toward methods for treating vasomotor symptoms, (e.g., hot flashes and night sweats) in a patient in need thereof comprising administering a SERM as described herein.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: January 13, 2015
    Assignee: Radius Health, Inc.
    Inventors: C. Richard Lyttle, Bart Henderson, Gary Hattersley
  • Patent number: 8916613
    Abstract: The invention relates to insecticide mixtures comprising thiodicarb and at least one other known active ingredient from the category of chloronicotinyls, as well as the use of these mixtures to control animal pests.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: December 23, 2014
    Assignee: Bayer CropScience AG
    Inventors: Wolfram Andersch, Heike Hungenberg, Wolfgang Thielert
  • Patent number: 8916558
    Abstract: This invention relates to powders for reconstitution comprising the NNRTI TMC278 dispersed in certain water-soluble polymers, which can be used in the treatment of HIV infection.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: December 23, 2014
    Assignee: Tibotec Pharmaceuticals Ltd.
    Inventors: Lieven Elvire Colette Baert, Elke Van Gyseghem, Guy René Jaak Van Den Mooter, Peter Jozef Maria Van Remoortere
  • Patent number: 8916612
    Abstract: The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: December 23, 2014
    Inventors: Gad Gilad, Varda Gilad
  • Patent number: 8911769
    Abstract: The invention relates to pharmaceutical compositions suitable for oral administration in the form of edible films comprising diclofenac.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: December 16, 2014
    Assignee: Novartis AG
    Inventors: Gavin Murray Spencer, Alexander Mark Schobel, Greg Slominski, Stephan Meyer, Isabelle Rault
  • Publication number: 20140350114
    Abstract: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.
    Type: Application
    Filed: August 7, 2014
    Publication date: November 27, 2014
    Inventors: Mahendra G. DEDHIYA, Shashank MAHASHABDE, Yan YANG, Anshu GOEL, Erhard SEILLER, Bernhard HAUPTMEIER
  • Publication number: 20140348932
    Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
    Type: Application
    Filed: August 6, 2014
    Publication date: November 27, 2014
    Inventors: Yan YANG, Rajiv JANJIKHEL, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Erhard SEILLER, Bernhard HAUPTMEIER
  • Patent number: 8883192
    Abstract: Compositions useful for weight management in an animal are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites, and in some embodiments include conjugated linoleic acid, and/or L-carnitine. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones, conjugated linoleic acid, and/or L-carnitine. Preferably, the compositions and methods employ a combination of one or more isoflavones, or a combination of one or more isoflavones in conjunction with conjugated linoleic acid, and L-carnitine.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: November 11, 2014
    Assignee: Nestec S.A.
    Inventor: Yuanlong Pan
  • Patent number: 8877814
    Abstract: The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: November 4, 2014
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Barbara Ellers-Lenz, Tanja Rosenberg, Erhard Seiller, Hagen Kruger, Michael Althaus
  • Patent number: 8877784
    Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: November 4, 2014
    Assignee: Abbvie Inc.
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
  • Patent number: 8877815
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: November 4, 2014
    Assignee: Novartis AG
    Inventors: Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Qian Liu, Muneto Mogi, Nikolaus Schiering, Robert Sun
  • Patent number: 8853281
    Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: October 7, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Anna Karin Belfrage, Bjorn Classon, Urszula Grabowska, Ellen Hewitt, Vladimir Ivanov, Daniel Jönsson, Pia Kahnberg, Peter Lind, Magnus Nilsson, Lourdes Odén, Mikael Pelcman, Horst Wähling
  • Patent number: 8846645
    Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: September 30, 2014
    Assignees: Rheinische Friedrich-Wilhelms Universität Bonn, Universität Konstanz
    Inventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
  • Publication number: 20140276484
    Abstract: Clay composite sheets, mats, films or membranes without polymers. Methods of preparing clay composite sheets, mats, films or membranes without using polymers in the method. Methods of using clay composite sheets, mats, films or membranes prepared without using polymers. Antimicrobial dressing having organo-modified clay product. Transdermal delivery of drugs using organo-modified clay product and methods.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Materials Modification Inc
    Inventors: Kausik Mukhopadhyay, Krishnaswamy Kasthuri Rangan, Tirumalai Srinivas Sudarshan
  • Patent number: 8834857
    Abstract: A method for cleaning, benefiting, or deodorizing skin or hair utilizing a body wash, skin cleaner, soap, shampoo or deodorizer formulation containing a controlled release skin benefit or deodorizing salt, a hydrophilic moisturizing polymer and surfactants is described. The method imparts benefits or deodorizing agents to the skin or hair and maintains effective levels for an extended period.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: September 16, 2014
    Assignee: Nevada Naturals Inc.
    Inventors: Anthony E. Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Patent number: 8835492
    Abstract: Disclosed is a block copolymer formed by coupling the following components with each other: (a) a copolymer (A) of a polyethylene glycol (PEG) type compound with a biodegradable polymer; and (b) at least one oligomer (B) selected from the group consisting of poly(?-amino ester) and poly(amido amine). A method for preparing the same block copolymer, and a polymeric hydrogel type drug composition comprising the temperature and pH-sensitive block copolymer and a physiologically active substance that can be encapsulated with the block copolymer are also disclosed. The multiblock copolymer is obtained by copolymerization of a pH-sensitive poly(?-amino ester) and/or poly(amido amine) type oligomer, a hydrophilic and temperature-sensitive polyethylene glycol type compound and a hydrophobic and biodegradable polymer.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 16, 2014
    Assignee: Sungyunkwan University Foundation for Corporate Collaboration
    Inventors: Doo Sung Lee, Min Sang Kim, Je Sun You, Huynh Dai Phu, Bong Sup Kim, Minh Khanh Nguyen
  • Patent number: 8828414
    Abstract: Provided are biocidal compositions comprising 2,6-dimethyl-m-dioxane-4-ol acetate and a non-formaldehyde releasing biocidal compound selected from the group consisting of: a brominated nitroalkanol, a 2-halo-2-(halomethyl)glutaronitrile, and 2-phenoxyethanol. The compositions are useful for controlling microorganisms in aqueous or water containing systems.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: September 9, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Kathy J. Ji, Donald J. Love, Jon B. Raymond
  • Patent number: 8822541
    Abstract: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: September 2, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Natalia A. Belikova, Jianfei Jiang, Joshua Pierce, Joel Greenberger, Michael Epperly, Valerian Kagan
  • Patent number: 8809578
    Abstract: The present invention relates to a novel compound having excellent antioxidant activity, isolated from Ramalina terebrata, and more particularly to a novel compound, RAMALIN™, having excellent antioxidant activity, isolated from the Antarctic lichen Ramalina terebrata, a method for preparing the RAMALIN™, and a pharmaceutical composition, a functional food and a functional cosmetic composition, which contain the RAMALIN™ as an active ingredient. The RAMALIN™ according to the invention has significantly excellent antioxidant effects compared to commercially available antioxidants, and thus can be widely used in agents for treating oxidation-related diseases, anti-aging functional foods, functional cosmetic products for skin whitening and wrinkle reduction, etc.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: August 19, 2014
    Assignee: Korea Ocean Research and Development Institute
    Inventors: Joung Han Yim, Hong Kum Lee, Hari Datta Bhattarai, Paudel Babita, Il Chan Kim, Soon Gyu Hong, Doc Kyu Kim, Yoo Kyung Lee, Sung Gu Lee, Hyun Cheol Oh
  • Publication number: 20140228440
    Abstract: The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.
    Type: Application
    Filed: March 20, 2014
    Publication date: August 14, 2014
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Peter Boderke, Alexander Gebauer, Bhushan Hardas, Bernhard Hauptmeier, Rainer Pooth
  • Patent number: 8802733
    Abstract: The present invention provides methods and compositions for reducing pigmentation.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: August 12, 2014
    Assignees: The Regents of the University of California, Board of Regents, The University of Texas System
    Inventors: Anand Ganesan, Michael A. White, Patrick J. Farmer
  • Patent number: 8785428
    Abstract: Use of an orally or nasally available formulation of Tretazicar for poisoning vermin. An orally available or nasally available formulation of Tretazicar, wherein in the orally available formulation the Tretazicar is protected from acid hydrolysis, and provided that the formulation is not solid Tretazicar in a gelatin capsule. A formulation of Tretazicar in which the Tretazicar is protected from acid hydrolysis, wherein the formulation is present in a liquid form. A combination of Tretazicar and bait. A method of poisoning vermin comprising making available to the vermin an orally or nasally available formulation of Tretazicar and allowing the vermin to ingest or inhale the formulation of Tretazicar.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: July 22, 2014
    Assignee: Morvus Technology Limited
    Inventors: Richard J. Knox, Roger Melton, Philip Burke
  • Patent number: 8784862
    Abstract: The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: July 22, 2014
    Assignee: Hemoteq AG
    Inventors: Roland Horres, Marita Katharina Linssen, Michael Hoffmann, Erika Hoffmann, Donate DiBiase, Volker Faust
  • Patent number: 8778923
    Abstract: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: July 15, 2014
    Assignee: Receptos, Inc.
    Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Adam R. Yeager, Enugurthi Brahmachary, Thomas Fowler, Andrew Novak, Premji Meghani, Michael Knaggs
  • Patent number: 8754041
    Abstract: The method of removing Escherichia coli (E. coli) bacteria from an aqueous solution includes the step of mixing multi-walled carbon nanotubes functionalized with a dodecylamine group (C12H27N) into an aqueous solution containing E. coli bacteria. The multi-walled carbon nanotubes functionalized with a dodecylamine group have an antimicrobial effect against the E. coli bacteria. The multi-walled carbon nanotubes may be mixed into the aqueous solution at a concentration of between approximately 0.2 g and 0.007 g of multi-walled carbon nanotubes functionalized with a dodecylamine group per 100 ml of the aqueous solution.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: June 17, 2014
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Muataz Ali Atieh, Amjad Bajes Khalil, Tahar Laoui, Samer Mohammed Al-Hakami
  • Patent number: 8741807
    Abstract: A compound useful as a plant activator for activating an endogenous defense system of a plant to control disease damage is provided. A compound represented by the formula: (R3)NH—(CH2)4—N(R1)—(CH2)3—NH(R2) (one of R1 and R2 represents a linear C6-18 alkanoyl group or alkenoyl group, the other represents hydrogen atom or a protective group of amino group; and R3 represents hydrogen atom or a protective group of amino group).
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: June 3, 2014
    Assignees: The University of Tokyo, National Institute of Agrobiological Sciences, Riken
    Inventors: Tadao Asami, Masashi Hikosaka, Masaki Mori, Satoru Maeda, Fumio Matsuda, Kazuki Saito
  • Patent number: 8709454
    Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: April 29, 2014
    Assignee: L'Oreal
    Inventors: David Amar, Bruno Bernard, Dominique Bernard, Isabelle Castiel
  • Publication number: 20140107212
    Abstract: The present invention relates to the treatment of an individual afflicted with mast cell mediated diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventor: Hjalmar KURZEN
  • Patent number: 8680149
    Abstract: The present invention relates to the treatment of an individual afflicted with mast cell mediated diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: March 25, 2014
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventor: Hjalmar Kurzen
  • Patent number: 8673982
    Abstract: This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: March 18, 2014
    Assignee: Novartis AG
    Inventors: Volker Brinkmann, Guido Jordine, Markus Zollinger, Claudia Sayer
  • Patent number: 8673979
    Abstract: S-alkylsiothiouronium derivatives such as S-ethylisothiouronium diethylphosphate are used for the treatment of headaches, in particular, migraines, as well as for the prevention or treatment of nausea and vomiting. The compositions of the invention are also effective in preventing or alleviating emesis associated with migraines or other medical conditions such as chemotherapy or radiotherapy, as well as other symptoms of migraines including phonophobia and photophobia.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: March 18, 2014
    Assignee: Meditor Pharmaceuticals Ltd.
    Inventors: Raphael Barkan, Alexander Mirimsky
  • Publication number: 20140066471
    Abstract: Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof in a fatty acid-based ionic liquid to form a composite ionic composition of the medicinal substance. The external preparation composition can be used as a liquid preparation, an ointment, a cream, a plaster or the like, and enables to provide a preparation having excellent transdermal absorbability.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Applicant: MEDRX CO., LTD.
    Inventors: Toshikazu YAMAGUCHI, Kenta KAWAI, Katsuhiro YAMANAKA, Noboru TATSUMI
  • Publication number: 20140066409
    Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.
    Type: Application
    Filed: December 13, 2011
    Publication date: March 6, 2014
    Applicants: UNIVERSITÄT KONSTANZ, RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN
    Inventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
  • Patent number: 8642635
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: February 4, 2014
    Assignee: Novartis AG
    Inventors: Yuki Iwaki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi
  • Patent number: 8642661
    Abstract: Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: February 4, 2014
    Assignee: Altherx, Inc.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Patent number: RE44704
    Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 14, 2014
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler